Optimizing Transition of Care in Multiple Myeloma: Bridging the Gap Between Academic and Community Settings : Episode 3
CAR T-Cell Therapy: Leukapheresis Practices
Myeloma specialists discuss their approaches to determining the optimal timing for leukapheresis for patients awaiting CAR T-cell therapy.
EP: 1.Identifying Potential Candidates for CAR T-Cell Therapy
EP: 2.Treating Patients Referred to Academic Centers for CAR T
Now Viewing
EP: 3.CAR T-Cell Therapy: Leukapheresis Practices
EP: 4.Triaging and Prioritizing Patients with Multiple Myeloma
EP: 5.Transitioning Patients Back to Community Practices Following CAR T
EP: 6.Monitoring Adverse Events Following CAR T-Cell Therapy
EP: 7.Educating Patients on Complications Associated with CAR T-Cell Therapy
EP: 8.Improving Access for Patients Receiving CAR T-Cell Therapy
EP: 9.Collaborative Education for CAR T-Cell Therapy
EP: 10.Evaluating the Use of CAR T-Cell Therapy for Multiple Myeloma in Academic and Community Settings
- What are the criteria used to determine the optimal timing for leukapheresis in relation to the bridging therapy regimen and disease burden?
- How is the leukapheresis procedure scheduled and coordinated between the community oncologist and the academic CAR-T center?
- How are patients monitored after leukapheresis while awaiting CAR-T manufacturing and infusion?
Recent Videos
Related Content
